tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BeOne Medicines price target raised to $350 from $340 at BofA

BofA analyst David Li raised the firm’s price target on BeOne Medicines (ONC) to $350 from $340 and keeps a Buy rating on the shares after “robust” sales growth in Q2, driven by strong Brukinsa sales in the U.S. and EU. Following the results and guidance, the firm raised its 2025, 2026 and 2027 revenue estimates by 1.3%, 1.7% and 2.3%, respectively.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1